csirt@kutim:~/threat-intel/cve/CVE-2026-46617

Katalog CVE

CVSS 8.7 · High EPSS 0,48%

Kerentanan Execution with Unnecessary Privileges. Skor CVSS 4.0 8.7 (High) menurut github.com.

Deskripsi (NVD)

Fission is an open-source, Kubernetes-native serverless framework that simplifies the deployment of functions and applications on Kubernetes. Prior to version 1.23.0, Fission runtime pods were created with ServiceAccountName: fission-fetcher, and the fission-fetcher ServiceAccount was granted namespace-wide get on secrets and configmaps (it needs that to load function code, env vars, and config). The runtime pod's automounted token was reachable from inside the user's function container at /var/run/secrets/kubernetes.io/serviceaccount/token, so user-supplied function code inherited the same Kubernetes API privileges and could read any secret or configmap in the function's namespace — far beyond the Function.spec.secrets allowlist that the function specification suggests. This issue has been patched in version 1.23.0.

Rincian

Terbit di NVD
10 Juni 2026
Terakhir diubah
17 Juni 2026
Status NVD
Deferred
CVSS 4.0
8.7 (High), sumber github.com
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-250: Execution with Unnecessary Privileges
CWE-269: Improper Privilege Management
CWE-538: Insertion of Sensitive Information into Externally-Accessible File or Directory
EPSS (30 hari)
0,48% peluang dieksploitasi; lebih tinggi dari 39,6% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.